bioplex 2200 ana screen (Bio-Rad)

Bio-Rad is a verified supplier

Bio-Rad manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Bio-Rad bioplex 2200 ana screen
Bioplex 2200 Ana Screen, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 96/100, based on 543 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bioplex+2200+ana+screen/BioPlex+2200+System/pmc13087645-101-13-19
Average 96 stars, based on 543 article reviews

bioplex 2200 ana screen - by Bioz Stars, 2026-10

96/100 stars

Images

Multiplex Assay:

Article Title: Autoantibody seroprevalence in clinical laboratory testing pre- and post-COVID-19
Article Snippet: .. Extractable nuclear antigen detection by multiplex flow immunoassay Extractable nuclear antigens (ENA) were assessed on the BioPlex 2200 ANA screen (Bio-Rad Laboratories, Inc., Hercules, CA), which is a multiplex flow immunoassay. ..

other:

Article Title:
Article Snippet: Analytical performance: a. Precision/Reproducibility Reproducibility testing for the BioPlex 2200 ANA Screen was conducted at three clinical sites located in the U.S. A reproducibility panel consisting of 33 panel members was prepared at Bio-Rad Laboratories.

Article Title: Increased Risk of Myositis-Specific and Myositis-Associated Autoantibodies After COVID-19 Pandemic and Vaccination: A Spanish Multicenter Collaborative Study
Article Snippet: Following a positive ANA test, extractable nuclear antigen (ENA) antibody screening was evaluated using two different immunoassays among the participating centers: the BioPlex 2200 ANA screen (Bio-Rad Laboratories, Hercules, CA, USA) and the APTIVA (CTD Essential, Werfen, Bedford, MA, USA).

Comparison:

Article Title:
Article Snippet: .. Comparison of BioPlex 2200 ANA Screen (Qualitative Screening Format) to Bio-Rad (Helix) Autoimmune EIA ANA Screening Test in Patients with Physician Diagnosed Targeted CTD (n=413): BioPlex 2200 ANA Screen Bio-Rad (Helix) EIA Positive Negative Total Positive 256 76 332 Negative 9 72 81 Total 265 148 413 Positive Agreement: 77.1% (256/332) Negative Agreement: 88.9% (72/81) Overall Agreement 79.4% (328/413) Comparison of BioPlex 2200 ANA Screen (Qualitative Screening Format) to Bio-Rad (Helix) Autoimmune EIA ANA Screening Test in Patients with Criteria Diagnosed Targeted CTD (n=408): BioPlex 2200 ANA Screen Bio-Rad (Helix) EIA Positive Negative Total Positive 268 67 335 Negative 9 64 73 Total 277 131 408 Positive Agreement: 80.0% (268/335) Negative Agreement: 87.7% (64/73) Overall Agreement 81.4% (332/408) Comparison of Selected Antibodies to EIA Methods (n=1047): Testing to evaluate the performance of the BioPlex 2200 ANA Screen compared to the individual predicate EIAs was conducted at three sites located in the U.S. using 907 samples collected prospectively from consecutive patients being seen in a rheumatology clinic and suspected of, or with a history consistent with an autoimmune/connective tissue disease. .. Additional selected retrospective (frozen) samples, known to be positive for one or more of the 11 analytes detected by the Bio-Rad BioPlex 2200 ANA Screen were selected for inclusion in the study.

Enzyme-linked Immunosorbent Assay:

Enzyme Immunoassay:

Immunofluorescence:

Article Title: Comparison study of bead-based and line-blot multiplex ANA immunoassays in the diagnosis of systemic autoimmune rheumatic diseases.
Article Snippet: Objectives Detection of antinuclear antibodies (ANA) by immunofluorescence assay (IFA) is increasingly substituted by multiplex bead-based immunoassay (MBA) and line-blot immunoassay (LIA).. This study is to compare the diagnostic performance of MBA and LIA ANA assays on clinically characterized patient samples.. Methods A total of 728 serum samples from 385 patients with systemic autoimmune rheumatic diseases (SARD), 204 patients with non-SARD diseases, and 139 apparently healthy subjects were tested with the BioPlex 2200 ANA Screen and EuroLine ANA Profile 3 as the representative MBA and LIA technologies and HEp-2 ANA IFA.

Review